News & Views | Published:

Antibody-drug conjugates ace the tolerability test

Nature Biotechnology volume 26, pages 884885 (2008) | Download Citation

Subjects

Near-uniform, low-level conjugation of cytotoxins to antitumor antibodies increases their tolerability without compromising efficacy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & Cancer J. 14, 154–169 (2008).

  2. 2.

    & Nat. Biotechnol. 23, 1137–1146 (2005).

  3. 3.

    Curr. Opin. Pharmacol. 5, 543–549 (2005).

  4. 4.

    Expert Opin. Biol. Ther. 4, 1445–1452 (2004).

  5. 5.

    et al. Nat. Biotechnol. 26, 925–932 (2008).

  6. 6.

    et al. Bioconjug. Chem. 16, 1282–1290 (2005).

  7. 7.

    et al. Protein Eng. Des. Sel. 7, 299–307 (2006).

  8. 8.

    et al. Clin. Cancer Res. 10, 7063–7070 (2004).

  9. 9.

    et al. J. Clin. Oncol. 26, Abstract 3025, presented at the 44th annual ASCO meeting, Chicago, IL, May 30–June 3, 2008.

Download references

Author information

Affiliations

  1. Nitin K. Damle was in the Oncology Discovery Research Division of Wyeth Research, Pearl River, New York 10965, USA.  ndamle56@gmail.com

    • Nitin K Damle

Authors

  1. Search for Nitin K Damle in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt0808-884

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing